Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bafetinib

Next Previous
Drug Profile

Bafetinib

Alternative Names: BCR-ABL/Lyn Kinase Inhibitors; CNS-9; INNO-406; NS-187

Latest Information Update: 07 May 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Shinyaku
  • Developer CytRx Corporation
  • Class Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Bone resorption; Brain cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 May 2014 Bafetinib is available for licensing as of 07 May 2014. http://www.cytrx.com
  • 18 Mar 2013 CytRx completes a phase I trial in Brain cancer in USA (NCT01234740)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top